Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

The FDA approval for Ponlimsi is based on comprehensive evidence, including analytical and clinical data.

Prolia should be covered by Medicare Part A, Part B, or Part D, depending on why you need to take the drug and whether you will administer it yourself. Prolia (denosumab) is an injectable monoclonal ...

On March 30, 2026, the FDA approved Ponlimsi, a biosimilar to Prolia, and is reviewing a biosimilar candidate for Xolair.

(RTTNews) - Alvotech (ALVO) announced that the European Commission has approved AVT03, a biosimilar to Amgen's Prolia and Xgeva for use across Europe. Prolia is indicated to treat osteoporosis and ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related conditions. The Patels added, "With the addition of two denosumab ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...